1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 10, 9, 1, 52 and 29 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 8 molecules, respectively.
Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Muscular Dystrophy - Overview
- Muscular Dystrophy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Muscular Dystrophy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Muscular Dystrophy - Companies Involved in Therapeutics Development
- Muscular Dystrophy - Drug Profiles
- Muscular Dystrophy - Dormant Projects
- Muscular Dystrophy - Discontinued Products
- Muscular Dystrophy - Product Development Milestones
- Featured News & Press Releases
- Oct 14, 2022: Avidity Biosciences announces upcoming presentation on AOC-1001 at 27th International Hybrid Annual Congress of World Muscle Society
- Oct 14, 2022: Avidity Biosciences announces upcoming presentation on AOC-1001 at 27th International Hybrid Annual Congress of World Muscle Society
- Sep 28, 2022: FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial
- Sep 27, 2022: Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
- Aug 04, 2022: Entrada Therapeutics announces collaboration with the Myotonic Dystrophy Clinical Research Network to study the natural history of myotonic dystrophy type 1
- Aug 02, 2022: Avidity Biosciences enrolls patients in the MARINA open-label extension study
- Jul 13, 2022: Fulcrum phase 3 FSHD clinical trial using AMRA Medical's Whole-body MRI Measurements as a Key Secondary Endpoint
- Jul 12, 2022: Dyne Therapeutics announces clearance of clinical trial application for DYNE-101 for the treatment of myotonic dystrophy type 1
- Jul 05, 2022: Fulcrum Therapeutics enrolls first patient in pivotal global Phase 3 clinical trial of Losmapimod for facioscapulohumeral muscular dystrophy (FSHD)
- Jun 20, 2022: New muscle disease indication for ATL1102 - Limb girdle muscular dystrophy R2
- May 17, 2022: NeuBase presents new preclinical data at ASGCT 2022 for its DM1 program demonstrating wide tissue distribution and supporting a differentiated whole-body treatment solution
- May 16, 2022: Dyne Therapeutics presents new in vivo data from DYNE-101 at ASGCT Annual Meeting demonstrating low monthly dosing leads to robust DMPK RNA knockdown
- May 16, 2022: Atamyo Therapeutics announces significant for ATA-100 to treat Limb-Girdle Muscular Dystrophy 2I/R9
- May 11, 2022: Entrada Therapeutics presents new data supporting its growing pipeline of Endosomal Escape Vehicle (EEV™) therapeutics, including ENTR-701 at TIDES USA 2022
- May 02, 2022: NeuBase Therapeutics announces presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Muscular Dystrophy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Muscular Dystrophy - Dormant Projects, 2022
- Muscular Dystrophy - Discontinued Products, 2022
- Number of Products under Development for Muscular Dystrophy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achelios Therapeutics Inc
- Altay Therapeutics Inc
- Amicus Therapeutics Inc
- AMO Pharma Ltd
- Anima Biotech Inc
- Antisense Therapeutics Ltd
- ARMGO Pharma Inc
- Arrowhead Pharmaceuticals Inc
- ARTHEx Biotech SL
- Asklepios BioPharmaceutical Inc
- Astellas Gene Therapies
- Atamyo Therapeutics SAS
- Avidity Biosciences Inc
- Beech Tree Labs Inc
- Benitec Biopharma Inc
- Biophytis SA
- Bioprojet SCR
- CalyGene Biotechnology Inc
- CANbridge Life Sciences Ltd
- Casma Therapeutics Inc
- Celularity Inc
- Chugai Pharmaceutical Co Ltd
- Constant Therapeutics LLC
- CRISPR Therapeutics AG
- Debiopharm International SA
- Design Therapeutics Inc
- DR.Noah Biotech Inc
- Dyne Therapeutics Inc
- Edgewise Therapeutics Inc
- Elixirgen Therapeutics Inc
- Entrada Therapeutics Inc
- Enzerna Biosciences LLC
- Epicrispr Biotechnologies Inc
- EpiSwitch Rx Inc
- Exodos Life Sciences Limited Partnership
- Expansion Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Facio Therapies BV
- Faze medicines
- Fulcrum Therapeutics Inc
- Generian Pharmaceuticals Inc
- Healx Ltd
- Hope Biosciences LLC
- Juvena Therapeutics Inc
- Keros Therapeutics Inc
- LinkedUp Bioscience Inc
- Locanabio Inc
- Loqus23 Therapeutics Ltd
- Lupin Ltd
- ML Bio Solutions Inc
- Modalis Therapeutics Corp
- Myocea Inc
- Myogem Health Company SL
- NeuBase Therapeutics Inc
- Nexien Biopharma Inc
- Nippon Shinyaku Co Ltd
- Nymirum Inc
- Pasithea Therapeutics Corp
- Pepgen Inc
- Pfizer Inc
- Phrixus Pharmaceuticals Inc
- Prothelia Inc
- QiXia Decode Therapeutics
- Recursion Pharmaceuticals Inc
- SanBio Co Ltd
- Sanofi
- Santhera Pharmaceuticals Holding AG
- Sarcomed AB
- Sarepta Therapeutics Inc
- Scriptr Global Inc
- SEAL Therapeutics AG
- Seelos Therapeutics, Inc.
- Siwa Therapeutics Inc
- Syros Pharmaceuticals Inc
- Triplet Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Vita Therapeutics Inc
- Xonovo Inc
